Overview of the QUILT Trial in BCG-Unresponsive NMIBC

"Overall, TAR-200 is being tested with the aim of changing the therapeutic paradigm of patients with an early bladder cancer diagnosis, including non–muscle-invasive disease and muscle-invasive disease," says Andrea Necchi, MD.

In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.

The phase 3 ENLIGHTED trial has reached the 50% patient enrollment threshold.

“We know that erectile dysfunction is really an important issue that can be a harbinger for other underlying cardiovascular or neurological health issues,” says Michael Lutz, MD.

The recommended phase 2 dose was determined to be rogaratinib at 600 mg in combination with atezolizumab at 1200 mg.

Enfortumab vedotin plus pembrolizumab was previously granted a priority review designation from the MHLW.